NCT03797092.

Study name	Stem cell therapy in non‐ischaemic non‐treatable dilated cardiomyopathies II: a pilot study
Methods	Open (2:1) RCT Follow‐up: 6 months
Participants	Adults aged 30–80 years with non‐ischaemic DCM
Interventions	SCT group: allogeneic adipose‐derived stromal cells (CSCC_ASC) Control: no treatment
Outcomes	Left ventricle end‐systolic volume (echocardiography) Allogeneic antibodies Changes in LVEF Change in echocardiogram‐measured global myocardial mass NYHA Kansas City Cardiomyopathy Questionnaire EQ‐5D3L Questionnaire 6‐minute walking test
Starting date
Contact information	Principal investigator: Jens Kastrup, MD, DMSc
Notes	Study completion date: 1 September 2021

AE: adverse event; BNP: brain natriuretic peptide; DCM: dilated cardiomyopathy; EQ‐5D3L: EQ‐5D three level version; LVEF: left ventricular ejection fraction; MACE: major adverse cardiovascular event; MRI: magnetic resonance imaging; MSC: mesenchymal stem cell; NYHA: New York Heart Association; RCT: randomized controlled trial; SAE: serious adverse event; SCT: stem cell therapy; SPECT: single‐photon emission computed tomography; VO₂: oxygen uptake.